Holdings of the Fund as of 10/30/2026
Total Number of Holdings (excluding cash): 50
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
68,808 |
$97,538,092.32 |
8.22% |
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
310,410 |
$91,536,804.90 |
7.71% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
2,796,755 |
$85,356,962.60 |
7.19% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
299,412 |
$81,799,358.40 |
6.89% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
538,680 |
$80,543,433.60 |
6.78% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
183,696 |
$46,588,979.52 |
3.92% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
271,946 |
$46,415,743.28 |
3.91% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
49,810 |
$46,218,200.90 |
3.89% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
2,410,534 |
$45,884,514.77 |
3.86% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
92,570 |
$43,138,545.70 |
3.63% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
69,224 |
$41,445,793.28 |
3.49% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
516,180 |
$41,149,869.60 |
3.47% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
73,085 |
$40,845,744.80 |
3.44% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
319,384 |
$38,450,639.76 |
3.24% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
595,681 |
$37,218,148.88 |
3.13% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
443,331 |
$30,762,738.09 |
2.59% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
126,533 |
$27,328,597.34 |
2.30% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
91,913 |
$21,690,548.87 |
1.83% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
159,787 |
$20,917,716.17 |
1.76% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
27,418 |
$17,876,810.18 |
1.51% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
38,508 |
$13,840,160.28 |
1.17% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
94,032 |
$13,738,075.20 |
1.16% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
233,064 |
$13,636,574.64 |
1.15% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
570,881 |
$13,164,515.86 |
1.11% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
57,003 |
$9,405,495.00 |
0.79% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
39,409 |
$8,737,763.48 |
0.74% |
| Caris Life Sciences, Inc. |
CAI |
142152107 |
Biotechnology |
217,020 |
$7,450,296.60 |
0.63% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
316,661 |
$6,811,378.11 |
0.57% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
19,466 |
$6,282,651.50 |
0.53% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
101,884 |
$6,233,263.12 |
0.53% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
88,582 |
$6,210,484.02 |
0.52% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
34,792 |
$6,220,809.60 |
0.52% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
39,795 |
$6,079,880.10 |
0.51% |
| Adaptive Biotechnologies Corporation |
ADPT |
00650F109 |
Biotechnology |
221,977 |
$5,913,467.28 |
0.50% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
46,567 |
$5,896,779.21 |
0.50% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
159,688 |
$5,894,084.08 |
0.50% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
61,920 |
$5,978,995.20 |
0.50% |
| Oruka Therapeutics, Inc. |
ORKA |
687604108 |
Biotechnology |
59,722 |
$5,785,270.14 |
0.49% |
| Iovance Biotherapeutics, Inc. |
IOVA |
462260100 |
Biotechnology |
677,104 |
$5,741,841.92 |
0.48% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
37,447 |
$5,424,197.95 |
0.46% |
| Tango Therapeutics, Inc. |
TNGX |
87583X109 |
Biotechnology |
242,202 |
$5,502,829.44 |
0.46% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
117,720 |
$5,337,424.80 |
0.45% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
15,401 |
$5,117,598.29 |
0.43% |
| Dianthus Therapeutics, Inc. |
DNTH |
252828108 |
Biotechnology |
52,392 |
$4,316,052.96 |
0.36% |
| Enliven Therapeutics Inc. |
ELVN |
29337E102 |
Biotechnology |
95,559 |
$4,228,485.75 |
0.36% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
83,453 |
$4,205,196.67 |
0.35% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
67,142 |
$4,021,805.80 |
0.34% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
191,341 |
$3,939,711.19 |
0.33% |
| Corcept Therapeutics Inc. |
CORT |
218352102 |
Pharmaceuticals |
48,806 |
$3,959,142.72 |
0.33% |
| Liquidia Technologies, Inc. |
LQDA |
53635D202 |
Biotechnology |
81,146 |
$3,656,438.76 |
0.31% |
| US Dollar |
$USD |
|
Other |
1,839,299 |
$1,839,299.07 |
0.15% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|